News
Novo Nordisk's next-gen weight loss drug outperforms Zepbound in new trial
Novo Nordisk says its potential Wegovy successor helped patients lose more weight than Zepbound in a major clinical trial.
More in Politics
- Healey tells party conference that money New Labour had in 1990s ‘is simply not there now’ – UK politics live The Guardian — Politics
- Hilton outlines English-only California schools plan The Hill
- Best thing we can offer young people is a job, not benefits, says chancellor BBC News — Politics
- SpaceX launches Starship on first orbital flight Axios
- Trump aims to leave a physical legacy in D.C., bulldozing norms along the way NPR — Politics